Welcome to our dedicated page for DermTech news (Ticker: DMTK), a resource for investors and traders seeking the latest updates and insights on DermTech stock.
DermTech, Inc. (DMTK) pioneers noninvasive molecular diagnostics for skin cancer detection, transforming dermatology through adhesive patch sampling and gene expression analysis. This page aggregates official announcements and verified developments about the company’s clinical advancements, financial updates, and operational milestones.
Investors and healthcare professionals will find timely updates on earnings reports, partnership agreements, and technological innovations. All content is curated to provide actionable insights into DermTech’s progress in reducing unnecessary biopsies through its CLIA-certified laboratory solutions.
Key updates include regulatory filings, research collaborations, and diagnostic technology enhancements. Each news item is vetted for relevance to the company’s mission of advancing precision dermatology while maintaining compliance with financial disclosure standards.
Bookmark this page for streamlined access to DermTech’s evolving role in molecular diagnostics. Regularly updated with press releases and objective analyses, it serves as your primary resource for tracking this innovator’s impact on noninvasive healthcare solutions.
DermTech, Inc. (NASDAQ: DMTK) announced the expansion of its Scientific Advisory Board with the addition of Dr. Klaus Busam, Dr. Joslyn Kirby, and Dr. Justin Ko. These industry leaders bring extensive experience in dermatology, dermatopathology, and genomics, enhancing DermTech's mission of transforming dermatology through its non-invasive skin genomics platform. The new members aim to support innovation and development in technologies impacting dermatological diseases. CEO John Dobak expressed optimism about their contributions to advance precision diagnostics and treatment options.
DermTech (NASDAQ: DMTK) announced its participation in upcoming investor conferences. The company will present at the 41st Annual William Blair Growth Stock Conference on June 1, 2021, at 4:20 PM ET, with a live webcast available on its website. DermTech will also attend the 18th Annual Craig-Hallum Institutional Investor Conference on June 2, 2021. DermTech leads in precision dermatology, utilizing a non-invasive skin genomics platform to enhance skin cancer detection and treatment personalization. More details can be found on DermTech’s investor relations site.
DermTech (NASDAQ: DMTK) reported Q1 2021 results highlighting a 175% increase in assay revenue to $2.2 million and a 62% total revenue increase to $2.5 million. Billable sample volume rose 62% to approximately 9,400. For the first time, the company achieved a positive assay gross margin of 10%, significantly up from -46% in Q1 2020. Despite these gains, a net loss of $15.1 million was reported, reflecting increased operational expenses. Management forecasts Q2 2021 assay revenue between $2.4 million and $2.8 million.
DermTech, Inc. (NASDAQ: DMTK) announced that its management will present at the UBS Global Healthcare Virtual Conference on May 24, 2021, at 4:00 p.m. Eastern Time. Interested individuals can access a live webcast and an archived version for 30 days post-event through the DermTech website.
DermTech is a leader in precision dermatology, utilizing a non-invasive skin genomics platform to enhance the detection of skin cancers and other diseases. Their innovative approach aims to democratize access to high-quality dermatology care.
DermTech, Inc. (NASDAQ: DMTK) recently presented at the 2021 Society for Investigational Dermatology (SID) virtual meeting. Chief Scientific Officer Michael Howell, PhD, discussed a study on Atopic Dermatitis (AD) that utilizes DermTech's non-invasive skin sampling technology. The research aims to better stratify AD patients based on their inflammatory signatures, which may lead to improved personalized treatments. DermTech is also initiating a prospective study to evaluate biologic treatments for AD. Current therapies are effective for less than 50% of patients, indicating a significant need for innovation.
DermTech (NASDAQ: DMTK) has launched the #Stickit2Melanoma campaign to raise awareness about skin exams during Melanoma Awareness Month. The initiative aims to encourage proactive skin health checks, as 1 in 5 Americans develop skin cancer by age 70. DermTech pledges up to $1 million over four years to donate $5 for each skin exam scheduled under the campaign. Early detection can lead to a 99% survival rate for localized melanoma. The campaign reflects DermTech's commitment to reducing melanoma deaths through its non-invasive testing technology.
DermTech, Inc. (NASDAQ: DMTK) will release its Q1 2021 financial results on May 13, 2021, after market closure. A conference call and webcast will follow at 1:30 p.m. Pacific time. Interested individuals can participate via telephone or through the company's website. DermTech is focused on precision dermatology, utilizing a non-invasive skin genomics platform to enhance skin cancer detection and treatment customization. The company emphasizes accessibility to quality dermatological care.
DermTech (NASDAQ: DMTK) has announced a collaboration with Stanford University School of Medicine to study biomarkers in Hidradenitis Suppurativa (HS), a chronic skin condition. The three-year research aims to enhance understanding and treatment of HS using DermTech's non-invasive genomics platform. This partnership emphasizes DermTech’s mission to improve patient outcomes in dermatology through advanced genomic techniques. The study is crucial as HS often remains undiagnosed for over seven years, highlighting the urgent need for better diagnostic methods.
DermTech, Inc. (NASDAQ: DMTK) has launched the DermTech PLAplus test, enhancing melanoma detection through TERT promoter DNA analysis. This advancement raises the sensitivity of the test from 91% to 97%, while maintaining a negative predictive value of over 99%. The introduction of PLAplus aids in early diagnosis, vital for improving patient outcomes. Recognized by the NCCN guidelines, DermTech’s non-invasive genomic testing leverages over 21 peer-reviewed studies and supports clinical decision-making for suspicious skin lesions.
DermTech (NASDAQ: DMTK) has joined The Skin Cancer Foundation Corporate Council, a network of over 100 companies committed to fighting skin cancer. This strategic partnership aims to promote education on skin checks and early diagnosis, which are crucial for survival, given that one in five Americans will face skin cancer in their lifetime. DermTech will also sponsor the Champions for Change Gala on May 11, 2021, supporting the Foundation's initiatives. The company emphasizes the importance of early detection in combating this deadly disease.
